Oral ezatiostat HCl (Telintra, TLK199) and idiopathic chronic neutropenia (ICN): A case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Lyons, Roger M ^a   Wilks, Sharon T ^a   Young, Shelby ^b   Brown, Gail L ^b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Telik Inc   (United States)

Author keywords

ezatiostat; idiopathic chronic neutropenia

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; ETANERCEPT; EZATIOSTAT; FISH OIL; HEMOGLOBIN; IBUPROFEN; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RHEUMATOID FACTOR; STEROID; DRUG DERIVATIVE; GAMMA GLU S BZCYS PHGLY DIETHYL ESTER; GAMMA-GLU-S-BZCYS-PHGLY DIETHYL ESTER; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; GRANULOCYTE COLONY STIMULATING FACTOR;

ABNORMAL FECES; ABNORMAL URINE COMPOSITION; ADULT; ARTICLE; BLOOD; BLOOD CELL COUNT; CASE REPORT; CELL HYPERPLASIA; DECUBITUS; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ERYTHROBLAST; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN CELL; HYPOPLASIA; IDIOPATHIC CHRONIC NEUTROPENIA; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTOSIS; MEGAKARYOCYTE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SEPSIS; SUPPRESSOR CELL; TREATMENT DURATION; TREATMENT OUTCOME; WOUND HEALING; DRUG ANTAGONISM; ENZYMOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ARTHRITIS, RHEUMATOID; FEMALE; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEUTROPENIA;

EID: 80055112021     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-43     Document Type: Article

References (18)

1. Neutropenia and Neutrophilia. Dale DC, Williams Hematology New York: McGraw-Hill, Williams W, Beutler E, Ersley A, Lichtman M, 8 2011 807
2. Treatment of cyclic neutropenia with testosterone. Brodsky I, Reimann HA, Dennis LH, Am J Med 1965 38 802
3. Correction of human cyclic neutropenia with prednisolone. Wright DG, Fauci AS, Dale DC, Wolff SM, N Engl J Med 1978 298 295
4. Effect of oxymetholone on human cyclic haematopoiesis. Roozendaal KJ, Dicke KA, Flaes MLB, Br J Haematol 1981 47 185
5. Cyclic neutropenia and T lymphocyte suppression of granulopoiesis: Abrogation of the neutropenic cycles by lithium carbonate. Verma DS, Spitzer G, Zander AR, Dicke KA, McCredie KB, Leuk Res 1982 6 567
6. Cyclic neutropenia: Amplification of granulocyte oscillations by lithium and long-term suppression of cycling by plasmapheresis. von Schulthess GK, Fehr J, Dahinden C, Blood 1983 62 320
7. Lithium therapy in childhood neutropenia. de Alarcon PA, Goldberg J, Nelson DA, Stockman JA, J Pediatr 1983 102 149
8. Treatment of idiopathic chronic neutropenia with high-dose intravenous immunoglobulin. Lakos A, Timar L, Am J Dis Child 1987 141 12
9. Alendronate reduces serum TNF alpha and IL-1 beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. Papadaki HA, Tsatsanis C, Christoforidou A, Malliaraki N, Psyllaki M, Pontikoglou C, Miliaki M, Margioris AN, Eliopoulos GD, J Bone Miner Metab 2004 22 6 577 87 (Pubitemid 39517878)
10. Phase 1 dose escalation study of TLK199 tablets (Telintra), a novel glutathione analog, in myelodysplastic syndrome. Raza A, Melchert M, Galili N, Smith S, Godwin J, Young S, Meng L, Jones M, Brown GL, Lancet J, List A, Proceedings of the Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8, 2007 Abstract 1454
11. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A, Blood 2009 113 26 6533 40
12. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Raza A, Galili N, Callender N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL, J Hematol Oncol 2009, 2 (20)
13. Phase 2 Randomized Multicenter study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Allison MA, Melnyk OG, Meng L, Jones M, Brown GL, Young S, Sekeres MA, Proceedings of the American Society of Hematology Annual Meeting, Orlando, FL, December 5, 2010 Abstract 2910
14. Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome. Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M, Cancer 2011
15. Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure. Quddus F, Clima J, Seedham H, Sajjad G, Galili N, Raza A, J Hematol Oncol 2010, 3 (16)
16. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GST pi) influences cell proliferation pathways. Ruscoe JE, Rosario LA, Wang T, Gate L, Arifoglu P, Wolf CR, Henderson CJ, Ronai Z, Tew KG, J Pharmacol Exp Ther 2001 298 1 339 45 (Pubitemid 32574545)
17. TLK199: A Novel, Small Molecule Myelostimulant. Meng F, Broxmeyer HE, Toavs D, Cristobal C, Morgan A, Gomez R, Wick MM, Kozlowski MR, Proceedings of the Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 25, 2001 Abstract 1144
18. Regulation of JNK signaling by GSTp. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ, Ronai Z, EMBO J 1999 18 5 1321 34 (Pubitemid 29110316)